X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (11) 11
infectious diseases (9) 9
hiv (7) 7
immunology (7) 7
clinical trials (6) 6
female (6) 6
humans (6) 6
male (6) 6
adult (5) 5
africa (5) 5
antiretroviral drugs (5) 5
hiv infections - drug therapy (5) 5
adolescent (4) 4
antiretroviral therapy (4) 4
antiviral agents (4) 4
child (4) 4
children (4) 4
drug therapy, combination (4) 4
human immunodeficiency virus--hiv (4) 4
microbiology (4) 4
mortality (4) 4
young adult (4) 4
adults (3) 3
africa south of the sahara (3) 3
aids/hiv (3) 3
care and treatment (3) 3
child, preschool (3) 3
drug therapy (3) 3
hiv infection (3) 3
hiv protease inhibitors - therapeutic use (3) 3
middle aged (3) 3
regimens (3) 3
resource-limited settings (3) 3
reverse transcriptase inhibitors - therapeutic use (3) 3
sub-saharan africa (3) 3
viral load - drug effects (3) 3
abacavir (2) 2
abridged index medicus (2) 2
adolescence (2) 2
adolescents (2) 2
advanced hiv disease (2) 2
aged (2) 2
analysis (2) 2
anti-hiv agents - administration & dosage (2) 2
anti-hiv agents - therapeutic use (2) 2
anti-retroviral agents - administration & dosage (2) 2
antiretroviral therapy, highly active (2) 2
biomarkers (2) 2
cd4 antigen (2) 2
cd4 lymphocyte count (2) 2
cohort (2) 2
developing countries--ldcs (2) 2
disease control (2) 2
disease progression (2) 2
dosage and administration (2) 2
drug dosages (2) 2
drug resistance (2) 2
efavirenz (2) 2
efficacy (2) 2
failure (2) 2
highly active antiretroviral therapy (2) 2
hiv infections - epidemiology (2) 2
hiv infections - virology (2) 2
hiv-1 - drug effects (2) 2
individuals (2) 2
infection (2) 2
infectious disease (2) 2
inflammation (2) 2
lopinavir (2) 2
lopinavir - therapeutic use (2) 2
lopinavir/ritonavir (2) 2
medical research (2) 2
medicine, general & internal (2) 2
morbidity (2) 2
nucleosides (2) 2
pediatrics (2) 2
raltegravir (2) 2
raltegravir potassium - administration & dosage (2) 2
raltegravir potassium - therapeutic use (2) 2
risk (2) 2
ritonavir - therapeutic use (2) 2
therapy (2) 2
treatment outcome (2) 2
trial (2) 2
usage (2) 2
virus diseases (2) 2
1st (1) 1
1st-line antiretroviral therapy (1) 1
acquired immune deficiency syndrome--aids (1) 1
africa - epidemiology (1) 1
africa south of the sahara - epidemiology (1) 1
age (1) 1
aids treatment (1) 1
amplification (1) 1
anti-hiv agents (1) 1
anti-infective agents - administration & dosage (1) 1
antiretroviral agents (1) 1
antiretroviral drug-resistance (1) 1
antiretroviral-naive subjects (1) 1
arachis (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS medicine, ISSN 1549-1676, 12/2018, Volume 15, Issue 12, p. e1002706
Background In sub-Saharan Africa, individuals infected with HIV who are severely immunocompromised have high mortality (about 10%) shortly after starting... 
MORTALITY | BIOMARKERS | SOUTH-AFRICA | MEDICINE, GENERAL & INTERNAL | IMMUNE RECONSTITUTION | EFAVIRENZ | ADULTS | INFECTION | RESTORATION | IMMUNODEFICIENCY | CHILDREN | HIV Infections - diagnostic imaging | Africa - epidemiology | Zimbabwe - epidemiology | Drug Administration Schedule | Follow-Up Studies | Kenya - epidemiology | HIV Infections - epidemiology | Humans | Raltegravir Potassium - administration & dosage | Child, Preschool | Malawi - epidemiology | Uganda - epidemiology | Male | Disease Progression | Anti-HIV Agents - administration & dosage | Young Adult | Anti-Retroviral Agents - administration & dosage | Adolescent | Adult | Female | HIV Infections - drug therapy | Child | Health Services Accessibility - trends | Drug therapy | HIV infection | Raltegravir | Testing | Adolescence | Therapy | RNA-directed DNA polymerase | Viremia | Funding | Clinical trials | Risk | Viruses | Infections | Tenofovir | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Children | Adolescents | Genotypes | Supervision | University colleges | Integrase | Antiretroviral drugs | Medical research | Mortality | Immune reconstitution | Inflammation | Disease control | Antiretroviral therapy | Morbidity | CD4 antigen | Medicine | Amplification | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Councils | Abacavir | Nucleosides | Biomarkers | Mutation | HIV | Human immunodeficiency virus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 234 - 247
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2016, Volume 71, Issue 5, p. 506
  To assess neurocognitive function at the first-line antiretroviral therapy failure and change on the second-line therapy. Randomized controlled trial was... 
Antiretroviral drugs | Clinical trials | Nervous system | Drug therapy
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2016, Volume 71, Issue 5, pp. 506 - 506
To assess neurocognitive function at the first-line antiretroviral therapy failure and change on the second-line therapy. Randomized controlled trial was... 
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 04/2016, Volume 71, Issue 5, pp. 506 - 513
Journal Article
by Hakim, James G and Thompson, Jennifer and Kityo, Cissy and Hoppe, Anne and Kambugu, Andrew and van Oosterhout, Joep J and Lugemwa, Abbas and Siika, Abraham and Mwebaze, Raymond and Mweemba, Aggrey and Abongomera, George and Thomason, Margaret J and Easterbrook, Philippa and Mugyenyi, Peter and Walker, A Sarah and Paton, Nicholas I and Agweng, E and Awio, P and Bakeinyaga, G and Isabirye, C and Kabuga, U and Kasuswa, S and Katuramu, M and Kiweewa, F and Kyomugisha, H and Lutalo, E and Mulima, D and Musana, H and Musitwa, G and Musiime, V and Ndigendawan, M and Namata, H and Nkalubo, J and Labejja, P Ocitti and Okello, P and Olal, P and Pimundu, G and Segonga, P and Ssali, F and Tamale, Z and Tumukunde, D and Namala, W and Byaruhanga, R and Kayiwa, J and Tukamushaba, J and Abunyang, S and Eram, D and Denis, O and Lwalanda, R and Mugarura, L and Namusanje, J and Nankya, I and Nankya, A and Ndashimye, E and Nabulime, E and Senfuma, O and Bihabwa, G and Buluma, E and Elbireer, A and Kamya, D and Katwere, M and Kiggundu, R and Komujuni, C and Laker, E and Lubwama, E and Mambule, I and Matovu, J and Nakajubi, A and Nakku, J and Nalumenya, R and Namuyimbwa, L and Semitala, F and Wandera, B and Wanyama, J and Mugerwa, H and Ninsiima, E and Ssenkindu, T and Mwebe, S and Atwine, L and William, H and Katemba, C and Acaku, M and Ssebutinde, P and Kitizo, H and Kukundakwe, J and Naluguza, M and Ssegawa, K and Namayanja and Nsibuka, F and Tuhirirwe, P and Fortunate, M and Acen, J and Achidri, J and Amone, A and Amone, G and Chamai, M and Ditai, J and Kemigisa, M and Kiconco, M and Matama, C and ... and Europe Africa Res Network and Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team
The Lancet Infectious Diseases, ISSN 1473-3099, 01/2018, Volume 18, Issue 1, pp. 47 - 57
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 2, pp. 169 - 179
Journal Article
by Mallewa, Jane and Szubert, Alexander J and Mugyenyi, Peter and Chidziva, Ennie and Thomason, Margaret J and Chepkorir, Priscilla and Abongomera, George and Baleeta, Keith and Etyang, Anthony and Etyang, Timothy and Warambwa, Colin and Melly, Betty and Mudzingwa, Shepherd and Kelly, Christine and Agutu, Clara and Wilkes, Helen and Nkomani, Sanele and Musiime, Victor and Musiime, Alex and Lugemwa, Abbas and Pett, Sarah L and Bwakura-Dangarembizi, Mutsa and Prendergast, Andrew J and Gibb, Diana M and Walker, Ann Sarah and Walker, A Sarah and Berkley, Jay and Berkley, James A and Kityo, Cissy and Wavamunno, Priscilla and Nambi, Esther and Ocitti, Paul and Ndigendawani, Milly and Kabahenda, Sheila and Kemigisa, Mable and Acen, Juliet and Olebo, David Francis and Mpamize, Gordon and Amone, Geoffrey and Amone, Alex and Okweny, David and Mbonye, Andrew and Nambaziira, Florence and Rweyora, Angela and Kangah, Mary and Kabaswahili, Beatrice and Abach, James and Omongin, Joseph and Aciro, Irene and Philliam, Aleti and Arach, Beatrice and Ocung, Emmanuel and Miles, Peter and Adong, Claudia and Tumsuiime, Constance and Kidega, Patrick and Otto, Ben and Apio, Florence and Mukuye, Andrew and Abwola, Mary and Ssennono, Fred and Baliruno, David and Tuhirwe, Stephen and Namisi, Ronald and Kigongo, Fredrick and Kikyonkyo, Dickson and Mushahara, Furaha and Tusiime, Julian and Nankya, Agnes and Atwongyeire, Dickens and Sirikye, Sowal and Myalo, Sula and Noowe, Nelson and Kasozi, Mariam and Mwebe, Sandra and Atwine, Lorna and Senkindu, Tapson and Natuhurira, Ian and Katemba, Chrispus and Ninsiima, Emily and Acaku, Moses and Kyomuhangi, Joy and Ankunda, Rogers and Tukwasibwe, Deogratious and Ayesiga, Lillian and Hakim, James and Nathoo, Kusum and Reid, Andrew and Mhute, Tawand and Tinago, Gloria and Bhiri, Joyline and Phiri, Misheck and Steamer, John and Nhema, Ruth and Musoro, Godfrey and Mutsai, Shirley and Nemasango, Beauty and Moyo, Columbus and Chitongo, Stuart and Rashirai, Kennias and ... and REALITY Trial Team and REALITY trial team
The Lancet HIV, ISSN 2352-3018, 05/2018, Volume 5, Issue 5, pp. e231 - e240
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2017, Volume 4, Issue 8, pp. e341 - e348
Journal Article
Clinical infectious diseases, ISSN 1058-4838, 2018, Volume 66, Issue suppl_2, pp. S140 - S146
Background. Severely immunocompromised human immunodefciency virus (HIV)-infected individuals have high mortality shortly afer starting antiretroviral therapy... 
mortality | immunosuppression | HIV | Africa | BIOMARKERS | INFECTIOUS DISEASES | INITIATION | MICROBIOLOGY | ANTIRETROVIRAL THERAPY | IMMUNOLOGY | INFECTED ADULTS | CHILDREN | Advanced HIV Disease
Journal Article